Complain about a product or service

British Heart Patients Told to Stop Taking Cox-2 Drugs

December 22, 2004
British drug regulators have officially advised patients with heart disease to stop taking COX-2 inhibitors Bextra, Celebrex and Vioxx.

COX-2 Drugs • Bextra • Celebrex • Vioxx --- News • Celebrex May Disrupt Heart Rhythm • FDA Rejects Arcoxia As Arthritis Drug • FDA Panel Rejects Vioxx Replacement • FDA Panel Members Indebted to Drug Companies • COX-2 Painkillers Restricted in Europe • Researchers Ignored Early COX-2 Warnings • FDA to Improve Drug Safety Monitoring • FDA Convenes COX-2 Meeting • FDA Blasts Ads For Celebrex, Bextra • Feds Issue Caution On All COX-2 Drugs • British Heart Patients Told to Stop Taking Cox-2 Drugs • Researchers Warn of Dangers

The Medicines and Healthcare Products Regulatory Agency (MHRA) issued a "Dear Doctor" letter following a study last week that found an increased risk of heart attacks and strokes in patients taking high doses of Pfizer's Celebrex.

"Patients treated with any COX-2 inhibitor who have established ischaemic heart disease or cerebrovascular disease should be switched to alternative (non-COX-2 selective) treatments as soon as is convenient," the agency said.

The letter also reminds doctors that all nonsteroidal anti-inflammatory drugs (NSAIDs), including COX-2 inhibitors, should be prescribed at the lowest effective dose for the shortest duration necessary. Other popular NSAIDs include naproxen, ibuprofen and aspirin.

"We are aware that new data from a clinical trial in the United States has indicated an increased cardiovascular risk (including heart attack and stroke) following treatment with celecoxib (Celebrex)," the agency said in a statement on its Web site.

"We have today issued a letter to healthcare professionals giving interim advice on prescribing of all COX-2 inhibitors, in light of emerging evidence, and have produced a question and answer document. Definitive advice will be issued, once further information is available and has been evaluated," it said.

"Patients receiving treatment with celecoxib (Celebrex) or other selective COX-2 inhibitors should not be alarmed and should make a non-urgent appointment with their GP to have their treatment reviewed," MHRA's statement concluded.

"For all patients, alternative treatments should be considered in light of an individual assessment of risks and benefits of COX-2 inhibitors, in particular cardiovascular, gastrointestinal and other risk factors," said Professor Gordon Duff, Chairman of the Committee on Safety of Medicines, the author of the letter.

MHRA noted that a recent letter to healthcare professionals from Pfizer, which highlighted the supposed cardiovascular safety of Celebrex, was "not authorised by the MHRA".

The latest Celebrex study, conducted by the US National Cancer Institute, found that the risk of heart attacks and strokes was 2.5 times higher in patients taking the 400-mg dose of the drug and 3.4 times higher with the 800-mg dose.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share		Follow us on Twitter.

Back to the top |

Terms of Use Your use of this site constitutes acceptance of the Terms of Use

Advertisements on this site are placed and controlled by outside advertising networks. ConsumerAffairs.com does not evaluate or endorse the products and services advertised. See the FAQ for more information.

Company Response Welcome If complaints about your company appear on our site, we welcome your response. Please see the Response Form for more information.

For more information, see the FAQ and privacy policy. The information on this Web site is general in nature and is not intended as a substitute for competent legal advice.  ConsumerAffairs.com Inc. makes no representation as to the accuracy of the information herein provided and assumes no liability for any damages or loss arising from the use thereof. 

Copyright © 2003-2009 ConsumerAffairs.com Inc.  All Rights Reserved.    The contents of this site may not be republished, reprinted, rewritten or recirculated without written permission.